|
? | |
購(gòu)買進(jìn)口儀器、試劑和耗材——就在始于2001年的畢特博生物 m.kjhfd.cn |
用激光發(fā)射裝置標(biāo)記敵方目標(biāo),引導(dǎo)戰(zhàn)斗機(jī)或轟炸機(jī)對(duì)其實(shí)施精確打擊。這是在好萊塢大片中經(jīng)常可以看到的場(chǎng)景,同時(shí)也是現(xiàn)代戰(zhàn)爭(zhēng)中地空協(xié)作的一個(gè)經(jīng)典范例。而日前由美國(guó)南加州大學(xué)研究人員完成的一項(xiàng)研究,有望讓這一戰(zhàn)術(shù)在人類與艾滋病的戰(zhàn)斗中獲得應(yīng)用,實(shí)現(xiàn)對(duì)艾滋病病毒(HIV)的精確打擊。 據(jù)美國(guó)每日科學(xué)網(wǎng)8月9日(北京時(shí)間)報(bào)道,南加州大學(xué)的研究人員日前培育出了一種病毒,其能夠作為載體精確定位被HIV病毒感染的細(xì)胞。這無(wú)疑為艾滋病這個(gè)“超級(jí)癌癥”的治療帶來(lái)了無(wú)限遐想,相關(guān)治療方法也有望因此獲得新突破。 負(fù)責(zé)該項(xiàng)研究的南加州大學(xué)維特比工程學(xué)院教授王品(音譯)說(shuō),由他們培育出的這種慢病毒載體能夠定位被HIV病毒感染的細(xì)胞,而后可采用“自殺基因療法”,讓后續(xù)藥物發(fā)現(xiàn)并將病毒細(xì)胞摧毀。這個(gè)過(guò)程類似于軍事上的“友軍激光標(biāo)記”——即地面戰(zhàn)斗人員使用激光發(fā)射裝置對(duì)敵方目標(biāo)進(jìn)行標(biāo)記,而后戰(zhàn)斗機(jī)在激光的引導(dǎo)下對(duì)目標(biāo)實(shí)施精確打擊。這種針對(duì)艾滋病病毒的慢病毒載體將只對(duì)那些被艾滋病病毒感染的細(xì)胞進(jìn)行標(biāo)記,未被感染的細(xì)胞則將完全處于不會(huì)受到傷害的“安全區(qū)域”,這就避免了治療所帶來(lái)的副作用。 “就目前而言,在單獨(dú)使用的情況下,還沒(méi)有任何藥物能夠?qū)崿F(xiàn)如此‘精確的打擊’。如果你能夠消滅掉所有被HIV病毒感染的細(xì)胞,將最終能夠找到解決問(wèn)題的辦法。”王品說(shuō)。 研究人員介紹說(shuō),目前這種慢病毒載體只在培養(yǎng)皿中進(jìn)行過(guò)測(cè)試。實(shí)驗(yàn)顯示,該法單次能夠殺滅35%的艾滋病病毒。雖然這一比例并不算高,但在應(yīng)用于臨床時(shí),可將其反復(fù)使用數(shù)次,以達(dá)到最佳療效。在接下來(lái)的步驟中,研究人員將使用這種方法進(jìn)行小鼠實(shí)驗(yàn)。 王品說(shuō),雖然這是一個(gè)重大的突破,為艾滋病的治療指明了一條新的路徑,但目前這項(xiàng)研究尚處于初級(jí)階段,距離治愈艾滋病還有很長(zhǎng)的一段路要走。 該項(xiàng)目由美國(guó)國(guó)立衛(wèi)生研究院(NIH)資助,相關(guān)論文發(fā)表在7月23日出版的《病毒研究》雜志上。
DOI:10.1016/j.virusres.2011.07.010 Engineered lentiviral vectors pseudotyped with a CD4 receptor and a fusogenic protein can target cells expressing HIV-1 envelope proteins Chi-Lin Lee, Jason Dang, Kye-Il Joo and Pin Wang Lentiviral vectors (LVs) derived from human immunodeficiency virus type 1 (HIV-1) are promising vehicles for gene delivery because they not only efficiently transduce both dividing and non-dividing cells, but also maintain long-term transgene expression. Development of an LV system capable of transducing cells in a cell type-specific manner can be beneficial for certain applications that rely on targeted gene delivery. Previously it was shown that an inverse fusion strategy that incorporated an HIV-1 receptor (CD4) and its co-receptor (CXCR4 or CCR5) onto vector surfaces could confer to LVs the ability to selectively deliver genes to HIV-1 envelope-expressing cells. To build upon this work, we aim to improve its relatively low transduction efficiency and circumvent its inability to target multiple tropisms of HIV-1 by a single vector. We investigated a method to create LVs co-enveloped with the HIV-1 cellular receptor CD4 and a fusogenic protein derived from the Sindbis virus glycoprotein and tested its efficiency to selectively deliver genes into cells expressing HIV-1 envelope proteins. The engineered LV system yields a higher level of transduction efficiency and a broader tropism towards cells displaying the HIV-1 envelope protein (Env) than the previously developed system. Furthermore, we demonstrated in vitro that this engineered LV can preferentially deliver suicide gene therapy to HIV-1 envelope-expressing cells. We conclude that it is potentially feasible to target LVs towards HIV-1-infected cells by functional co-incorporation of the CD4 and fusogenic proteins, and provide preliminary evidence for further investigation on a potential alternative treatment for eradicating HIV-1-infected cells that produce drug-resistant viruses after highly active antiretroviral therapy (HAART). |
購(gòu)買進(jìn)口儀器、試劑和耗材——就在始于2001年的畢特博生物
m.kjhfd.cn |
|